RFP
TEVA icon

Root Financial Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Root Financial Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-714
Closed -$21.5K – 2894
2026
Q1 		$21.5K Buy
714
+45
+7% +$1.45K ﹤0.01% 1287
2025
Q4 		$20.9K Buy
669
+18
+3% +$443 ﹤0.01% 1170
2025
Q3 		$13.2K Buy
+651
New +$11.4K ﹤0.01% 1322

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Root Financial Partners's TEVA Position: Q2 2026 in Review

Root Financial Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 714 shares — an estimated $21.5K sold.

Root Financial Partners first reported a position in TEVA in Q3 2025 and held it in 3 quarters. The position peaked at $21.5K in Q1 2026. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Root Financial Partners reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 714 Teva Pharmaceuticals shares in Q2 2026, an estimated $21.5K.
  • Root Financial Partners first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's Teva Pharmaceuticals position peaked at $21.5K in Q1 2026.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.